Skip to main content
Contact Us
Subscribe
E-Edition
62°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Best of 2024
Archives
2025 Calendar Photos
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Amarin Corporation plc
< Previous
1
2
Next >
Amarin Appoints Peter Fishman Chief Financial Officer
December 13, 2024
From
Amarin Corporation plc
Via
GlobeNewswire
Tickers
AMRN
Investigators to Present New REDUCE-IT Subanalysis of VASCEPA®/VAZKEPA® (icosapent ethyl) in Patients With and Without Coronary Artery Disease History and Mechanistic Data on Eicosapentaenoic Acid (EPA) at the American Heart Association’s (AHA) Annual
November 11, 2024
From
Amarin Corporation plc
Via
GlobeNewswire
Tickers
AMRN
Amarin Reports Third Quarter 2024 Financial Results and Provides Business Update
October 30, 2024
From
Amarin Corporation plc
Via
GlobeNewswire
Tickers
AMRN
Amarin Announces Two Upcoming Investor Events
October 01, 2024
From
Amarin Corporation plc
Via
GlobeNewswire
Tickers
AMRN
Research Highlighting the Clinical Impact of VASCEPA®/VAZKEPA (icosapent ethyl) in Patients with Diabetes and High Cardiovascular Risk and the Anti-Lp(a) Oxidation Mechanistic Effect of Eicosapentaenoic Acid (EPA) to be Presented at the 60th Annual
September 09, 2024
From
Amarin Corporation plc
Via
GlobeNewswire
Tickers
AMRN
Latest Research Highlighting VASCEPA®/VAZKEPA® (icosapent ethyl) REDUCE-IT® Subgroup Data and New Mechanistic Insights into Eicosapentaenoic Acid (EPA) to be Presented at European Society of Cardiology (ESC) Congress
August 22, 2024
From
Amarin Corporation plc
Via
GlobeNewswire
Tickers
AMRN
Amarin Reports Second Quarter 2024 Financial Results and Provides Business Update
July 31, 2024
From
Amarin Corporation plc
Via
GlobeNewswire
Tickers
AMRN
Amarin Receives National Reimbursement for VAZKEPA® (icosapent ethyl) in Portugal
July 17, 2024
From
Amarin Corporation plc
Via
GlobeNewswire
Tickers
AMRN
Amarin to Report Second Quarter 2024 Financial Results and Host Conference Call on July 31, 2024
July 17, 2024
From
Amarin Corporation plc
Via
GlobeNewswire
Tickers
AMRN
Amarin Partner EddingPharm Receives Regulatory Approval for VASCEPA® (Icosapent Ethyl) in Mainland China for Cardiovascular Risk Reduction (CVRR)
July 08, 2024
From
Amarin Corporation plc
Via
GlobeNewswire
Tickers
AMRN
Amarin Board of Directors Announces CEO Transition
June 04, 2024
From
Amarin Corporation plc
Via
GlobeNewswire
Tickers
AMRN
Amarin Receives National Reimbursement for VAZKEPA® (icosapent ethyl) in Greece and Announces Exclusive Marketing and Commercialization Agreement with Vianex S.A.
May 28, 2024
From
Amarin Corporation plc
Via
GlobeNewswire
Tickers
AMRN
Amarin to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference
May 06, 2024
From
Amarin Corporation plc
Via
GlobeNewswire
Tickers
AMRN
Amarin Reports First Quarter 2024 Business Update and Financial Results
May 01, 2024
From
Amarin Corporation plc
Via
GlobeNewswire
Tickers
AMRN
Amarin Applauds HealthyWomen’s Citizen’s Petition Urging FDA To Take Further Action On Fenofibrate Prescribing in Patients at Risk of Cardiovascular Event
April 24, 2024
From
Amarin Corporation plc
Via
GlobeNewswire
Tickers
AMRN
Amarin Announces Results of Annual General Meeting of Shareholders
April 22, 2024
From
Amarin Corporation plc
Via
GlobeNewswire
Tickers
AMRN
Amarin to Report First Quarter 2024 Financial Results and Host Conference Call on May 1, 2024
April 15, 2024
From
Amarin Corporation plc
Via
GlobeNewswire
Tickers
AMRN
Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ACC.24
April 08, 2024
From
Amarin Corporation plc
Via
GlobeNewswire
Tickers
AMRN
New REDUCE-IT® Analyses Show VASCEPA®/VAZKEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups
April 06, 2024
From
Amarin Corporation plc
Via
GlobeNewswire
Tickers
AMRN
Amarin Provides Update on VAZKEPA® (Icosapent Ethyl) Intellectual Property Portfolio in Europe
April 03, 2024
From
Amarin Corporation plc
Via
GlobeNewswire
Tickers
AMRN
Research Evaluating Benefits of VASCEPA®/VAZKEPA® (icosapent ethyl) to be Presented at the American College of Cardiology’s (ACC) Annual Scientific Session & Expo
March 25, 2024
From
Amarin Corporation plc
Via
GlobeNewswire
Tickers
AMRN
Amarin Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
February 29, 2024
From
Amarin Corporation plc
Via
GlobeNewswire
Tickers
AMRN
Amarin to Report Fourth Quarter and Full Year 2023 Financial Results and Host Conference on February 29, 2024
February 15, 2024
From
Amarin Corporation plc
Via
GlobeNewswire
Tickers
AMRN
Amarin Chairman & CEO Issue Letter to Shareholders
January 22, 2024
From
Amarin Corporation plc
Via
GlobeNewswire
Tickers
AMRN
Amarin Provides Preliminary Fourth Quarter 2023 Selected Financials and Outlines Key Priorities For 2024
January 10, 2024
From
Amarin Corporation plc
Via
GlobeNewswire
Tickers
AMRN
Amarin to Present at the 42nd Annual J.P. Morgan Healthcare Conference
December 11, 2023
From
Amarin Corporation plc
Via
GlobeNewswire
Tickers
AMRN
New REDUCE-IT® Analyses Show VASCEPA® (icosapent ethyl) Associated with 29 Percent Relative Risk Reduction Compared with Placebo in Prespecified Subgroup of Patients with Metabolic Syndrome, but Without Diabetes at Baseline
November 12, 2023
From
Amarin Corporation plc
Via
GlobeNewswire
Tickers
AMRN
Amarin Reports Third Quarter 2023 Financial Results
November 01, 2023
From
Amarin Corporation plc
Via
GlobeNewswire
Tickers
AMRN
Amarin Appoints Jonathan Provoost Executive Vice President, Chief Legal & Compliance Officer
October 31, 2023
From
Amarin Corporation plc
Via
GlobeNewswire
Tickers
AMRN
Latest Research Evaluating VASCEPA®/VAZKEPA® (icosapent ethyl) and Subgroups from the REDUCE-IT Landmark Outcomes Trial to be Presented at the American Heart Association (AHA) Scientific Sessions 2023
October 26, 2023
From
Amarin Corporation plc
Via
GlobeNewswire
Tickers
AMRN
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.